KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Travere Therapeutics (TVTX) Accumulated Depreciation & Amortization (2016 - 2025)

Travere Therapeutics' Accumulated Depreciation & Amortization history spans 11 years, with the latest figure at $60.7 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization rose 39.46% year-over-year to $60.7 million; the TTM value through Dec 2025 reached $60.7 million, up 39.46%, while the annual FY2025 figure was $60.7 million, 39.46% up from the prior year.
  • Accumulated Depreciation & Amortization reached $60.7 million in Q4 2025 per TVTX's latest filing, up from $43.6 million in the prior quarter.
  • In the past five years, Accumulated Depreciation & Amortization ranged from a high of $60.7 million in Q4 2025 to a low of $12.7 million in Q4 2021.
  • Average Accumulated Depreciation & Amortization over 5 years is $35.3 million, with a median of $38.5 million recorded in 2023.
  • Peak YoY movement for Accumulated Depreciation & Amortization: tumbled 48.14% in 2021, then surged 85.96% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $12.7 million in 2021, then skyrocketed by 62.55% to $20.7 million in 2022, then soared by 85.96% to $38.5 million in 2023, then grew by 13.04% to $43.6 million in 2024, then skyrocketed by 39.46% to $60.7 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Accumulated Depreciation & Amortization are $60.7 million (Q4 2025), $43.6 million (Q4 2024), and $38.5 million (Q4 2023).